Rare Daily Staff
Evox Therapeutics, which is developing a platform to allow drugs to be delivered across the blood-brain barrier and to tissue that can be difficult to target, said it completed a $45.4 million (£35.5 million) series B financing.
Redmile Group led the financing with significant new investments from GV (formerly Google Ventures) and Cowen Healthcare Investments, alongside investments from Panacea Healthcare Venture, Borealis Ventures, and a small number of private investors. Existing investors, Oxford Sciences Innovation and Oxford University also participated in the round.
The company said it will use the proceeds from this financing to advance its exosome-based therapeutics pipeline, including progression of several proprietary rare disease assets towards the clinic, and continued development of its platform.
Evox is engineering exosomes, the body’s natural vesicular delivery system, to enable a wide variety of drugs to reach previously inaccessible tissues and compartments, such as crossing the blood brain barrier to deliver drugs to the central nervous system, intracellular delivery of biologics, and extra-hepatic delivery of RNA therapeutics.
In addition to developing its own pipeline, Evox also continues to form partnerships with major pharmaceutical companies to fully exploit the use of exosome-based therapeutics for the treatment of a wide variety of other diseases.
“We are excited by the inherent transformational potential of our exosome technology, which significantly improves and enables the delivery of a wide range of therapeutic molecules, including antibodies, proteins, nucleic acids, and small molecules,” said Antonin de Fougerolles, CEO of Evox. “This additional funding will enable us to advance our pipeline of novel exosome-based therapeutics towards the clinic and allow continued expansion of our world-leading exosome platform.”
September 4, 2018
Photo: Antonin de Fougerolles, CEO of Evox